Myriad Genetics (MYGN) Misses Q1 EPS by 7c; Maintains Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Jefferies Maintains 'Hold' Rating on Myriad Genetics (MYGN) Post Q1, Estimates Lowered
November 5, 2014 8:42 AM ESTJefferies lowered estimates while maintaining a Hold rating and $37 price target on Myriad Genetics (NASDAQ: MYGN) following Q1 results.
Analyst Brandon Couillard commented, "MYGN's 1Q15 results were in line with its recent pre-release, but its initial 2Q guidance also fell well below... More
